Stock Alert for HBSC! September 13, 2006

Market Wire, September, 2006

Stock Market Alert's performance stock list includes: Human Biosystems (OTCBB: HBSC), ATI Technologies (NASDAQ: ATYT), VeriSign Incorporated (NASDAQ: VRSN), Eli Lilly and Company (NYSE: LLY).

Human Biosystems (OTCBB: HBSC) has released news that should get the attention of speculative investors this morning. Yesterday, after the stock markets closed, the company issued a press release announcing that a pre-IND (Investigational New Drug) application meeting with the FDA (Food and Drug Administration) has been scheduled for early October to discuss HBS's plan to conduct human infusion tests using the company's patented platelet preservation system.

This could be huge news for the company and it should get the attention of traders. The Pre-IND meeting is a prelude to a formal application and request to proceed with human testing once all concerns and requirements of the FDA are satisfied. The planned studies will involve a number of human subjects that are infused with platelets stored in the cold using the HBS process and compared to platelets prepared using the current storage method. The platelets are uniquely labeled prior to infusion to distinguish the HBS platelets from the control group, and monitored for platelet survival in the bloodstream over time.

Dr. David Lucas, Director of Platelet Development for HBS, stated that, "Studies have shown that standard blood platelets stored in the cold for 24 hours or longer are not functional and are quickly eliminated from the blood after infusion. It is our goal to show that HBS platelets will maintain functionality and continue to circulate in the bloodstream for more than a few hours and ideally even for days after infusion. The HBS platelets will be stored at refrigerated temperatures for several days prior to infusion."

The advantages of the HBS cold stored platelets are potentially longer shelf life, fresher and higher quality platelets, cost savings due to fewer platelet transfusions and significant savings of expenses due to the reduction of outdates compared to platelets stored under current methods.

This continues to be a stock for speculative investors to watch. Dr. David Winter, President of HBS, confirmed that, "The basis for proceeding to human infusion studies is the result of positive in-vitro test data obtained at two independent research centers in the United States. This Pre-IND meeting is a positive step toward our goal to demonstrate that cold stored platelets using HBS technology can maintain functionality after storage for more than 24 hours, which to our knowledge, has never been demonstrated before."

Blood platelets are the congealing component in blood, and are an essential part of the treatment for cancer patients who have undergone chemotherapy. Current regulations provide for the storage of platelets at room temperature for 5 days.

Human BioSystems is a developer of preservation platforms for organs and other biomaterials. The Company, which is headquartered in Palo Alto, California with research facilities in Michigan, has made significant progress in its nine-year history. This scheduled meeting is another milestone for Human BioSystems in achieving its goal to commercialize its technologies.

Prior to the news being released, the stock closed yesterday at fourteen cents per share.

A profile of Human BioSystems can be found here: http://www.wallstreettradingalerts.com/HBSC091206.html .

Other Stocks of interest yesterday were:

ATI Technologies (NASDAQ: ATYT) up 1% on 7.3 million shares traded. ATI Technologies Inc. is one of the leaders in the design and manufacture of innovative 3D graphics, PC platform technologies and digital media silicon solutions.

VeriSign, Inc., (NASDAQ: VRSN) up 5.5% on 7.2 million shares traded. VeriSign, Inc., operates intelligent infrastructure services that enable and protect billions of interactions every day across the world's voice and data networks.

Eli Lilly and Company (NYSE: LLY) up 1.6% on 7.5 million shares traded. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.

Wall Street Enews is a Sponsor of Quality Stocks. Quality Stocks tracks the stock picks of 150 Investment Newsletters every day and reports on their performance. For Their Free Service, Visit www.qualitystocks.net .

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company received compensation for services performed for Human Biosystems (OTCBB: HBSC). The compensation is fourteen thousand dollars from the company. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.